Entera Bio (ENTX) News Today → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free ENTX Stock Alerts $2.02 -0.03 (-1.22%) (As of 09:43 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?investorplace.com - April 15 at 3:43 PMEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 988.9% in Marchmarketbeat.com - April 10 at 12:36 PMEntera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Researchglobenewswire.com - April 8 at 8:30 AMQ1 2024 EPS Estimates for Entera Bio Ltd. (NASDAQ:ENTX) Lifted by HC Wainwrightmarketbeat.com - April 4 at 8:33 AMEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Monthsglobenewswire.com - March 26 at 8:30 AMWe Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growthfinance.yahoo.com - March 23 at 12:04 PMEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndromeglobenewswire.com - March 20 at 8:00 AMEntera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 12 at 12:14 AMENTX May 2024 5.000 callfinance.yahoo.com - March 9 at 6:55 PMEntera Bio Announces Full Year 2023 Financial Results and Provides Business Updatesglobenewswire.com - March 8 at 4:05 PMEntera Bio regains NASDAQ compliance with bid priceinvesting.com - March 6 at 6:27 PMEntera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirementfinanznachrichten.de - March 4 at 10:52 AMEntera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirementglobenewswire.com - March 4 at 8:30 AMENTX Mar 2024 2.500 callfinance.yahoo.com - February 17 at 12:36 AMEntera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - January 30 at 9:27 AMENTX Jan 2024 10.000 callca.finance.yahoo.com - January 20 at 5:25 PMEntera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rulefinance.yahoo.com - January 3 at 9:24 AMEntera Bio Stock (NASDAQ:ENTX), Short Interest Reportbenzinga.com - December 31 at 12:18 PMEntera Bio Stock (NASDAQ:ENTX) Dividends: History, Yield and Datesbenzinga.com - December 27 at 12:31 PMEntera Bio Stock (NASDAQ:ENTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 26 at 3:00 PMEntera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025finance.yahoo.com - December 26 at 10:00 AMInterim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platformfinance.yahoo.com - November 29 at 12:26 PMEntera Bio (ENTX) Price Target Increased by 66.67% to 10.20msn.com - November 27 at 10:40 AMEntera Bio Flat on Release of Q3 Numbersbaystreet.ca - November 14 at 3:03 PMEntera Bio GAAP EPS of -$0.08msn.com - November 14 at 10:03 AMEntera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Developmentfinance.yahoo.com - November 14 at 10:02 AMEntera Bio Ltd ENTXmorningstar.com - November 11 at 10:43 AMEntera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosisfinance.yahoo.com - November 9 at 4:34 PMEntera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meetingfinance.yahoo.com - October 16 at 10:45 AMOPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulationsfinance.yahoo.com - September 13 at 4:27 PMEntera Bio to Participate in Upcoming Investor Conferencesfinance.yahoo.com - September 5 at 10:19 AMEntera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meetingfinance.yahoo.com - August 16 at 8:55 AMEntera Bio Ltd.: Entera Bio Announces Q2 2023 Financial Results and Corporate Updatesfinanznachrichten.de - August 12 at 10:40 AMEntera Bio Announces Q2 2023 Financial Results and Corporate Updatesfinance.yahoo.com - August 11 at 7:38 PMEntera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directorsfinanznachrichten.de - June 7 at 3:14 PMEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directorstechnews.tmcnet.com - June 7 at 10:14 AMEntera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)finance.yahoo.com - May 7 at 9:57 AMEntera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate Updatesfinanznachrichten.de - May 6 at 7:30 AMEntera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimatesfinance.yahoo.com - May 5 at 10:46 PMEntera Bio: Q1 Earnings Insightsmsn.com - May 5 at 5:46 PMEntera Bio Announces Q1 2023 Financial Results and Corporate Updatesfinance.yahoo.com - May 5 at 5:46 PMEntera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeuticstechnews.tmcnet.com - May 3 at 1:33 PMEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeuticsfinance.yahoo.com - May 3 at 1:33 PMMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Boardmarketwatch.com - April 27 at 8:50 AMMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Boardfinance.yahoo.com - April 26 at 9:45 AMHC Wainwright & Co. Reiterates Entera Bio (ENTX) Buy Recommendationmsn.com - April 4 at 7:13 PMH.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)markets.businessinsider.com - April 4 at 9:12 AMEntera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Programfinance.yahoo.com - April 3 at 9:50 AMEntera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimatesfinance.yahoo.com - March 31 at 10:48 PMEntera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022finance.yahoo.com - March 31 at 5:47 PM Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about... Click here to see Louis' new video for yourself. ENTX Media Mentions By Week ENTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTX News Sentiment▼1.000.46▲Average Medical News Sentiment ENTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTX Articles This Week▼00▲ENTX Articles Average Week Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cidara Therapeutics News Today Instil Bio News Today Turnstone Biologics News Today Aligos Therapeutics News Today Genenta Science News Today Elutia News Today Ikena Oncology News Today Semper Paratus Acquisition News Today Cognition Therapeutics News Today Gritstone bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
